Legend Biotech Corporation (LEGN): one to watch?

Business fundamentals are genuinely improving (first profitable quarter, 50%+ drug sales growth) but a sudden CEO exit and dilution add real uncertainty — worth watching, not an obvious buy yet.

👀 WATCH Fundamentals65/100

Down 76% from its all-time high of $76.50 — now $18.64

$70.1$16.2 peak $66 202420252026

Why LEGN dropped

The long decline from 2023 highs reflects a slower-than-hoped commercial ramp for its cancer drug Carvykti and competitive threats, but 2026 has brought real improvement: 50% revenue growth and Legend's first-ever profitable quarter. However, the stock separately dropped sharply in July 2026 when the CEO abruptly resigned, and the company also diluted shareholders with a $226M stock sale in June 2026 to shore up cash.

Fwd P/E 17.7Op margin 14.9%Rev growth 51.9%Debt/equity 22.6%Analyst upside 160.4%
How this scored 65/100
✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.
✅ Makes money Loss-making today, but operations are profitable (14.9%) and analysts expect positive earnings next year
✅ Generates cash Free cash flow $27M
✅ Not drowning in debt Debt/equity 22.6% (limit 200%)
✅ Can pay its bills Current ratio 3.0 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 5/25
Operating margin 14.9% 5/9
Net profit margin -7.2% 0/8
Return on equity -8.1% 0/8
Growth Is it getting bigger, or dying? 19/25
Revenue growth 51.9% 9/9
Earnings growth unknown 2/8
Expected profit change 310.0% 8/8
Value Is it cheap right now? 16/25
Forward P/E 17.7 7/10
PEG ratio unknown 2/8
Analyst target upside 160.4% 7/7
Balance sheet Will it survive? 25/25
Debt / equity 22.6% 10/10
Current ratio 3.0 8/8
Free cash flow $27M 7/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for LEGN — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-09-23. Research only — not financial advice.